Download This Paper
Preprints with The Lancet is a collaboration between The Lancet Group of journals and SSRN to facilitate the open sharing of preprints for early engagement, community comment, and collaboration. Preprints available here are not Lancet publications or necessarily under review with a Lancet journal. These preprints are early-stage research papers that have not been peer-reviewed. The usual SSRN checks and a Lancet-specific check for appropriateness and transparency have been applied. The findings should not be used for clinical or public health decision-making or presented without highlighting these facts. For more information, please see the FAQs.
Persistence of Anti-HAV Antibody and Long-Term Protection Conferred by a Single Dose of Live-Attenuated Hepatitis a Vaccine: Results from 17-Year Follow-Up
27 Pages Posted: 8 Oct 2018
More...Abstract
OBJECTIVES: With implementation of mass immunization and improvements in sanitation, China is moving rapidly from high to low endemicity of hepatitis A (HA). To prevent a resurgence after intense vaccination, a comprehensive and systematic assessment of long-term protection against HA conferred by vaccine is needed.
METHODS: In 1996, 3,515 susceptible children aged one to 12 years were recruited in a randomized, open trial to assess the efficacy of a live-attenuated HA vaccine. During a 17-year follow-up period, children were tested for antibody persistence and long-term protection against both hepatitis A virus (HAV) disease and infection. Case finding was conducted using the China National Notifiable Infectious Disease Reporting System. Serum anti-HAV antibody levels were evaluated by the ELISA method to ascertain antibody persistence and protection against infection.
RESULTS: During the 17-year follow-up, 2,132 (61%) children from the initial cohort were available for analysis. After calibrating the sensitivity of assay, excluding natural infection and vaccine booster, the sero-positive rate and the geometric mean concentrations declined from 94.9% and 131.3 mIU/mL (91.5-188.4mIU/mL) at the peak to 55.6% and 41.1 mIU/mL (95% CI: 27.8-61.0 mIU/mL) respectively, with a similar natural infection rate in both groups. Notably, a cumulative protection against HAV of 94.0% (95% CI: 54.5% - 99.2%) was measured 17 years after initial HAV vaccination.
CONCLUSIONS: This study demonstrates that long-term protection against hepatitis A persists at least for 17 years after administration of a single dose of a live-attenuated HA vaccine and suggests that a booster dose is currently not necessary.
Funding: This work was supported by grants from National Natural Science Foundation (China) (81072346).
Declaration of Interest: The authors declare that they have no competing interests.
Ethical Approval: This study was reviewed and approved by the Institutional Review Board of the Institutes of Biomedical Sciences, Fudan University. Written inform consent was obtained from each participant.
Keywords: Hepatitis A virus; Live attenuated vaccine; Anti-HAV; Persistence; Protection
Suggested Citation: Suggested Citation